1,626,940 Shares in Roivant Sciences Ltd. $ROIV Bought by Maverick Capital Ltd.

Maverick Capital Ltd. purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 1st quarter, Holdings Channel.com reports. The fund purchased 1,626,940 shares of the company’s stock, valued at approximately $45,066,000.

Several other institutional investors have also added to or reduced their stakes in the business. Pictet Asset Management Holding SA boosted its holdings in Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock valued at $50,180,000 after acquiring an additional 2,052,693 shares during the period. Capricorn Fund Managers Ltd increased its stake in Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after purchasing an additional 247,000 shares during the period. Vanguard Group Inc. increased its stake in Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares during the period. Exchange Traded Concepts LLC bought a new stake in Roivant Sciences in the fourth quarter valued at approximately $5,435,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock valued at $1,746,000 after purchasing an additional 38,354 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Down 0.8%

Shares of ROIV stock opened at $34.72 on Tuesday. The stock has a fifty day moving average of $32.36 and a 200 day moving average of $28.77. Roivant Sciences Ltd. has a 52 week low of $10.90 and a 52 week high of $37.00. The firm has a market capitalization of $24.97 billion, a price-to-earnings ratio of -57.87 and a beta of 1.11.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ROIV. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Guggenheim increased their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Citigroup raised their price target on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Insiders Place Their Bets

In other news, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the sale, the director owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. The trade was a 5.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This represents a 11.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,855,913 shares of company stock worth $62,649,633. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.